Therefore, the use of SOX11 by immunohistochemistry can improve the diagnosis of SCLC and aggressive neuroendocrine lung cancer subgroups, which is beneficial for clinical risk stratification and selection of appropriate treatment methods. This evidence concerns the gene SOX11 and small cell lung carcinoma.